Corrigendum to "Mutation Spectrum of the ABCA4 Gene in a Greek Cohort with Stargardt Disease: Identification of Novel Mutations and Evidence of Three Prevalent Mutated Alleles".

[This corrects the article DOI: 10.1155/2018/5706142.].

Central corneal thickness in patients with neovascular age-related macular degeneration.

PURPOSE: To compare the central corneal thickness (CCT) measurements of patients with neovascular age-related macular degeneration (AMD) and control subjects. METHODS: The CCT value (measured with ultrasound corneal pachymetry) of 130 eyes (130 patients, 1 eye from each patient) with neovascular AMD (AMD group) and 98 eyes (98 patients, 1 eye from each patient) of similar age, sex, and eye's axial length healthy control subjects (normal group) was compared. RESULTS: The mean age (AMD group: 69.1 years vs. control group: 69.5 years, P = 0.81), sex (AMD group: 77 women, 59% vs. control group: 59 women, 60%, P = 0.77), and eye's axial length (AMD group: 25.05-mm vs. control group: 24.61-mm, P = 0.38) of patients with neovascular AMD and healthy control subjects were comparable. There were no statistically significant differences in the mean CCT measurements in the neovascular AMD group in comparison with the control group (549.44 vs. 544.35 microm, P = 0.11). CONCLUSIONS: CCT measurements do not differ in patients with neovascular AMD compared with healthy control subjects.

The effect of intense, short-term topical dexamethasone disodium phosphate eyedrops on blood glucose level in diabetic patients.

AIM: To evaluate the influence of an intensive course of topical (ophthalmic drops) steroid (dexamethasone disodium phosphate) application on blood glucose levels in diabetic patients. METHODS: Fifty-five diabetic (type 2) patients were randomly assigned to receive either corticosteroid (study group: 30 patients, 1 drop of 0.1% dexamethasone disodium phosphate) or balanced salt solution (BSS; control group: 25 patients) eyedrops, every 2 h for 7 days (8 drops/day). Blood glucose monitoring (venous blood sample) was performed at the same time every day (10:00 a.m.). RESULTS: During the study no side effects (such as hypoglycemic/hyperglycemic crises) were observed in either study or control group. No statistically significant alterations in blood glucose levels were found (p = 0.19, paired t test) in either group. In the corticosteroid group, when we separately examined patients with controlled diabetes mellitus (initial glucose level or=135 mg/dl), while for control patients we did not find any statistically significant differences in any group. CONCLUSIONS: Intensive application of topical corticosteroids (drops) for a short period of time (7 days) seems to statistically raise the blood glucose levels in patients with controlled diabetes mellitus, which, however, return to pretreatment levels after discontinuation of eyedrops without any side effects.